AN2 Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: ANTX · Form: 8-K · Filed: May 27, 2025 · CIK: 1880438
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
TL;DR
AN2 Therapeutics filed an 8-K on shareholder votes, standard corporate governance.
AI Summary
AN2 Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting on matters submitted to a vote of security holders as of May 22, 2025. The filing details the company's corporate structure, including its incorporation in Delaware and principal executive offices in Menlo Park, California.
Why It Matters
This filing indicates a formal process of shareholder engagement and decision-making, which is crucial for corporate governance and strategic direction.
Risk Assessment
Risk Level: low — This is a routine corporate filing regarding shareholder votes, not indicating any immediate financial or operational distress.
Key Numbers
- 001-41331 — SEC File Number (Identifies the company's filing history with the SEC.)
- 82-0606654 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Menlo Park, California (location) — Principal Executive Offices
- May 22, 2025 (date) — Earliest event reported
- May 27, 2025 (date) — Filing Date
FAQ
What specific matters were submitted to a vote of AN2 Therapeutics' security holders?
The filing indicates that matters were submitted to a vote, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 22, 2025.
What is AN2 Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 1800 El Camino Real, Suite D, Menlo Park, California, 94027.
Under which state is AN2 Therapeutics, Inc. incorporated?
AN2 Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for AN2 Therapeutics, Inc.?
The SEC file number is 001-41331.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 27, 2025 regarding AN2 Therapeutics, Inc. (ANTX).